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ACKR2 in hematopoietic precursors as a
checkpoint of neutrophil release and anti-
metastatic activity
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Atypical chemokine receptors (ACKRs) are regulators of leukocyte trafﬁc, inﬂammation, and
immunity. ACKR2 is a scavenger for most inﬂammatory CC chemokines and is a negative
regulator of inﬂammation. Here we report that ACKR2 is expressed in hematopoietic pre-
cursors and downregulated during myeloid differentiation. Genetic inactivation of ACKR2
results in increased levels of inﬂammatory chemokine receptors and release from the bone
marrow of neutrophils with increased anti-metastatic activity. In a model of NeuT-driven
primary mammary carcinogenesis ACKR2 deﬁciency is associated with increased primary
tumor growth and protection against metastasis. ACKR2 deﬁciency results in neutrophil-
mediated protection against metastasis in mice orthotopically transplanted with 4T1 mam-
mary carcinoma and intravenously injected with B16F10 melanoma cell lines. Thus, ACKR2 is
a key regulator (checkpoint) of mouse myeloid differentiation and function and its targeting
unleashes the anti-metastatic activity of neutrophils in mice.
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Chemokines are key components of tumor microenviro-ment1,2. Production of chemokines sustains unresolvingchronic inﬂammation, which promotes carcinogenesis.
Moreover, oncogene activation drives chemokine production and
leukocyte recruitment in tumors epidemiologically unrelated to
inﬂammatory conditions3.
The repertoire of chemokines produced in the context of
neoplastic tissues shapes the leukocyte inﬁltrate1,2. For instance,
CCL2 and CXCL8, and related CC and CXC chemokines, are
major determinants of macrophage and neutrophil recruitment,
respectively. CCL17 and CCL22 have been associated with
recruitment of Th2 and regulatory T (Treg) cells, which tame
effective antitumor immunity. Conversely, CXCL10 driven
recruitment of CD8 T cells and Th1 cells is a driver of antitumor
resistance1,2,4.
Chemokine and chemokine receptors are important determi-
nants of invasion and metastasis5. For instance, the chemokine
repertoire expressed by tumor cells impacts on secondary seeding
at distant sites such as the brain or lymph nodes6. Moreover
inﬂammatory chemokines precondition the metastatic niche and
drive tumor cell seeding at sites of secondary localization7.
Canonical chemokine receptors are seven transmembrane G
protein-coupled receptors. Mature leukocyte subsets express
distinct repertoires of signaling chemokine receptors8. Moreover,
the chemokine system includes a limited set (four) of atypical
chemokine receptors (ACKRs). ACKRs bind a broad panel of
inﬂammatory (ACKR1 and ACKR2) or homeostatic (ACKR3 and
ACKR4) chemokines and regulate ligand availability by acting as
decoys, scavengers, transporters, or depots9–11.
ACKR2 (previously known as D6) acts as a decoy and sca-
venger for most inﬂammatory CC chemokines and is expressed
by lymphatic endothelial cells, trophoblasts in the placenta, and
some leukocytes such as innate B cells and alveolar macro-
phages11. In line with its scavenger function, ACKR2 is a negative
regulator of inﬂammation at different anatomical sites11.
Inﬂammation is a key component of the tumor microenviron-
ment12. Accordingly, genetic inactivation of ACKR2 unleashes
tumor-promoting inﬂammation in the skin and gastrointestinal
(GI) tract13–15. Moreover, downregulation of ACKR2 in trans-
formed cells has been associated with tumor progression and
oncogene activation in Kaposi sarcoma16–18.
The present study stems from an unexpected observation. In
line with previous carcinogenesis results13,14, in an oncogene-
driven mammary carcinoma model we found that ACKR2-
deﬁcient mice show enhanced tumor growth at the primary
tumor site. In contrast, ACKR2 gene-targeted mice are protected
against metastasis. This unexpected ﬁnding, extended to trans-
planted tumors, prompted a dissection of underlying mechan-
isms. We found that ACKR2 is expressed in hematopoietic
progenitor cells (HPCs) and that it serves as a key regulator
(checkpoint) of myeloid differentiation and function. Targeting
ACKR2 unleashes the anti-metastatic potential of neutrophils.
Results
Ackr2−/− mice are protected against tumor metastasis. In order
to extend previous studies on ACKR2 in carcinogenesis, we
crossed Balb/c Ackr2−/− mice with Balb/c NeuT mice, which
overexpress the rat Her2/neu oncogene under the mouse mam-
mary tumor virus promoter and spontaneously develop mam-
mary carcinomas closely recapitulating human breast
carcinogenesis19. We followed primary tumor development
measuring time of appearance and volume, and found that in
NeuT/Ackr2−/− mice tumor masses in mammary glands devel-
oped earlier (Supplementary Fig. 1a) and reached higher volumes
as compared to NeuT/Ackr2+/+ mice (Fig. 1a). This result is in
accordance with previous reports showing that ACKR2 genetic
deﬁciency results in increased growth of primary tumors13,14.
Unexpectedly, lung analysis revealed less metastatic lesions in
NeuT/Ackr2−/− mice as compared to NeuT/Ackr2+/+ mice
(Fig. 1b, c).
In an effort to strengthen and extend these ﬁndings, the
transplanted tumor lines 4T1 (mammary carcinoma) and B16F10
(melanoma) were used. 4T1 tumor cells were transplanted
orthotopically, whereas B16F10 melanoma cells were injected
intravenously (i.v.) in a classic “artiﬁcial” hematogenous metas-
tasis model (see below).
When 4T1 cells were injected into the mammary glands of
wild-type (WT) and Ackr2−/− mice, no difference in primary
tumor growth was detected (Fig. 1d), but again the number of
spontaneous lung metastasis was signiﬁcantly lower in Ackr2−/−
mice (Fig. 1e, f). Since 4T1 cells expressed little or no Ackr2,
before and after in vivo growth (Supplementary Fig. 1B), these
results suggested that the regulatory function of ACKR2 on
metastasis is not cancer cell-intrinsic.
In order to understand which cells protect mice from
metastasis, bone marrow (BM) chimeric mice were orthotopically
injected with 4T1 cells. Mice were protected from metastasis only
when Ackr2 was genetically inactivated in the hematopoietic
compartment (Supplementary Fig. 1c), demonstrating that
protection phenotype was due to hematopoietic expression of
ACKR2.
Increased myeloid cell mobilization in Ackr2−/− mice. The two
breast cancer models used in our experiments are known to
induce expansion and mobilization of myeloid cells, which then
promote tumor growth20,21. Interestingly, when animals were
challenged with the 4T1 sibling cell line 66cl4, which in contrast
is unable to induce myeloid cell expansion and is less meta-
static22,23, we did not ﬁnd any difference in the number of
metastatic lesions between WT and Ackr2−/− mice (Fig. 1f). We
therefore focused on effects of ACKR2 genetic inactivation on the
myeloid compartment of tumor-bearing mice as a potential
mechanism of protection from metastasis.
NeuT/Ackr2+/+ mice, at 25 weeks of age, have an increased
number of circulating Ly6Chigh monocytes and Ly6G+ neutro-
phils (Fig. 2a, b, respectively; gating strategy in Supplementary
Fig. 2a) compared with Balb/c WT mice20,21. As we previously
reported24, Ackr2−/− mice have increased number of circulating
Ly6Chigh monocytes (Fig. 2a), while no signiﬁcant difference was
found in the number of neutrophils (Fig. 2b) compared to WT
mice. At 25 weeks of age, NeuT/Ackr2−/− mice presented a
further signiﬁcant increase of blood monocytes and neutrophils
(Fig. 2a, b) compared to Ackr2−/− and NeuT/Ackr2+/+, indicating
that the lack of ACKR2 was a further driver of tumor-induced
myelopoiesis and/or BM release of myeloid cells.
Increased number of inﬂammatory monocytes and neutrophils,
but not alveolar or interstitial macrophages, were also detected in
the lungs of NeuT/Ackr2−/− as compared to NeuT/Ackr2+/+ mice
(Fig. 2c and Supplementary Fig. 2b for the gating strategy), while
in basal conditions no difference was found between leukocyte
inﬁltrate in the lung of WT and Ackr2−/− mice (Supplementary
Fig. 2c). A higher number of Ly6G+ neutrophils in the
parenchyma of NeuT/Ackr2−/− lungs compared to
NeuT/Ackr2+/+ mice was also found by immunohistochemistry,
conﬁrming the ﬂow cytometry data (Fig. 2d, e). Similar results
were obtained analyzing blood and lungs of WT and Ackr2−/−
mice orthotopically injected with 4T1 cells (Supplementary
Fig. 2d,e, respectively). In these mice, analysis of myeloid cells
in the BM 14 days after tumor injection showed a reduced
number of monocytes and neutrophils in Ackr2−/− compared to
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WT mice (Fig. 2f). These results indicate that in tumor
conditions, Ackr2−/− mice show enhanced release of myeloid
cells from BM, which then accumulate in the blood and lungs.
Increased chemokine-induced mobilization in Ackr2−/− mice.
To investigate the role of ACKR2 in myeloid cells egress from the
BM, we performed leukocyte mobilization experiments. As pre-
viously reported and as shown in Fig. 3a, under homeostatic
conditions, ACKR2-deﬁcient mice have increased frequency and
absolute number of circulating Ly6Chigh monocytes compared to
WT and a concomitant decrease in the frequency of the same
cells in the BM (Fig. 3c), whereas they showed similar number of
circulating and BM neutrophils24 (Fig. 3b, d). After injection of
CCL3L1, an ACKR2 ligand known to induce rapid mobilization
of both neutrophils and monocytes25, Ackr2−/− mice showed a
signiﬁcant higher number of circulating monocytes and neu-
trophils compared to WT littermates (Fig. 3a, b, respectively).
Concomitantly, the decrease in monocytes and neutrophils in the
BM caused by CCL3L1 injection was more pronounced in
Ackr2−/− animals (Fig. 3c, d, respectively).
BM chimera experiments showed that both WT and Ackr2−/−
hosts when transplanted with Ackr2−/−, but not WT, hemato-
poietic cells had an increased number of circulating monocytes
and neutrophils (Fig. 3e, f; Supplementary Fig. 3a,b) and higher
number of monocytes and neutrophils inﬁltrating the lung
(Supplementary Fig. 3c,d). These results demonstrated that the
increased mobilization of monocytes and neutrophils induced by
CCL3L1 injection was caused by the absence of ACKR2 in the
hematopoietic compartment.
Finally, in order to understand whether there is a different
localization of leukocytes in the BM sinusoids of ACKR2-
deﬁcient mice, we performed in vivo labeling experiments of
monocytes with a 2-minute pulse of anti-Ly6C-PE antibody as
previously described26. In ACKR2-deﬁcient BM sinusoids there
was a signiﬁcant higher percentage of monocytes located in this
vascular compartment after chemokine-induced mobilization
compared to WT controls (Supplementary Fig. 3e,f).
Neutrophils protect Ackr2−/− mice from metastasis. To inves-
tigate the relevance of the increased myeloid cell mobilization
found in Ackr2−/− mice in the metastatic process, the B16F10
melanoma cell line was injected i.v. in a classic “artiﬁcial”
hematogenous metastasis model. In this experimental setting,
Ackr2−/− mice showed increased number of circulating neu-
trophils while no differences were found in the number of cir-
culating monocytes, and T and B lymphocytes compared to WT
mice (Supplementary Fig. 4a). Also in this model, there was a
signiﬁcant reduction in the metastatic ratio in the lungs of
ACKR2-deﬁcient hosts compared to WT animals (Fig. 4a). In
order to understand which cells were responsible for metastasis
protection, we performed depletion experiments by using
monoclonal antibodies. Monocyte depletion by treatment with an
α-CD115 monoclonal antibody signiﬁcantly decreased the num-
ber of metastasis in WT mice, but did not reverse the protection
observed in Ackr2−/− mice (Supplementary Fig. 4b). We then
performed neutrophil depletion with an α-Ly6G monoclonal
antibody. Neutrophil depletion caused a reduction in metastasis
in WT mice while an increase in metastatic ratio was observed in
Ackr2−/− mice (Fig. 4b). The protective role of neutrophils in
Ackr2−/− mice was also demonstrated by performing depletion
experiments with the ortotopically transplanted 4T1 tumor line.
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Fig. 1 Ackr2−/− mice are protected from lung metastasis. a NeuT/Ackr2+/+ (white squares) and NeuT/Ackr2−/− (black squares) mice were evaluated for
tumor growth calculated as described in the Materials and Methods section (n= 42 for NeuT/Ackr2+/+ and 23 for NeuT/Ackr2−/− mice). b Representative
images of hematoxylin and eosin staining of NeuT/Ackr2+/+ and NeuT/Ackr2−/− lungs at 25 weeks of age. Magniﬁcation: ×10. Scale bar: 3 mm. c
Metastatic ratio of NeuT/Ackr2+/+ (white column) and NeuT/Ackr2−/− (black column) mice, calculated as described in the Materials and Methods section
(n= 26 and NeuT/Ackr2+/+ and 16 for NeuT/Ackr2−/− mice, respectively). d Tumor volume in WT (white symbols) and Ackr2−/− (black symbols) mice
injected orthotopically with 4T1 cells (n= 14 for WT and 13 for Ackr2−/− mice). e Representative images of hematoxylin and eosin staining of WT and
Ackr2−/− lungs at day 28 after 4T1 cell injection. Magniﬁcation: ×10. Scale bar: 3 mm. f Metastatic ratio of WT (white columns) and Ackr2−/− (black
columns) mice at day 28 after orthotopic injection of 4T1 or 4T1 66cl4 cells (n= 14 for WT and 13 for Ackr2−/− mice for 4T1, 4 for both WT and Ackr2−/−
mice for 4T1 66cl4). Data are represented as mean (SD). p value was generated using the unpaired t-test. *p< 0.05, **p< 0.01, ns= not statistically
different
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Also in this model, neutrophil depletion reduced the metastatic
ratio in WT mice, while it increased metastasis in Ackr2−/− hosts
(Fig. 4c). Finally, since ACKR2 was reported to be expressed by B
lymphocytes27, we performed B lymphocyte depletion using an α-
CD20 monoclonal antibody with no rescue of the metastasis
phenotype associated with ACKR2 deﬁciency (Supplementary
Fig. 4c).
The role of Ackr2−/− neutrophils in protection against
metastasis was further investigated by adoptive cell transfer
experiment. Transfer of Ackr2−/−, but not WT, neutrophils into
WT tumor-bearing mice signiﬁcantly reduced the metastatic ratio
(Fig. 4d) to values comparable to those observed in Ackr2−/−
tumor-bearing mice.
Increased tumor-killing activity of Ackr2−/− neutrophils. As
depletion and adoptive transfer experiments clearly pointed to
neutrophils as the key elements responsible for protection against
metastasis observed in the absence of ACKR2, we evaluated their
reactive oxygen species (ROS) production, one of the main
mechanism of tumor cell-killing. Neutrophils from B16F10-
bearing Ackr2−/− animals produced signiﬁcantly higher amounts
of ROS compared to WT mice (Fig. 5a). Similar results were
obtained analyzing neutrophils in 4T1-bearing WT and Ackr2−/−
mice (Supplementary Fig. 5a).
Ackr2−/− neutrophils also showed a signiﬁcant increase in
transcript levels of the chemokine receptors Ccr1, Ccr2, and Ccr5,
but not Cxcr4 (Fig. 5b), while expression levels of other genes
associated with neutrophils activation, including Tnf-α, Alox5,
Vegf-a, and Arg1, were not different between WT and Ackr2−/−
cells (Fig. 5c). Adoptive transfer experiments demonstrated that
Ackr2−/− neutrophils display increased recruitment to the lung
compared to WT neutrophils with a concomitant reduction of
their number in the blood (Fig. 5d, e, respectively).
Chemokines were reported to control not only neutrophil
recruitment to metastatic sites but also their potential anti-
metastatic functions such as ROS production28. We therefore
examined whether the increased levels of CC chemokine
receptors found on Ackr2−/− neutrophils could result in increased
ROS production. Compared to WT cells, Ackr2−/− neutrophils
produced more ROS already under resting conditions and even
more after stimulation with the CCR2 ligand CCL2 (Fig. 5f).
In order to assess the functional relevance of this observation,
circulating neutrophils were isolated from tumor-bearing mice
and evaluated for their ability to kill tumor cells in vitro.
Neutrophils obtained from Ackr2−/− mice displayed an increased
tumor-killing activity (Fig. 5g) compared to cells isolated from
WT mice. The killing activity of both WT and Ackr2−/−
neutrophils was partially reversed by the ROS inhibitor apocynin.
Similar results were obtained with neutrophils isolated from
resting WT and Ackr2−/− mice (Supplementary Fig. 5b).
Collectively, these results suggest that neutrophil activation
during tumor progression is constrained by ACKR2, which
impinges on their expression of CC chemokine receptors
and inhibits their migration to the lung and their ability to
generate ROS, key mediators of neutrophil antitumoral
potential29,30.
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Fig. 2 Protection from metastasis in Ackr2−/− mice is associated with increased numbers of monocytes and neutrophils in blood and lungs. a Absolute
number of circulating inﬂammatory monocytes (CD45+/CD11b+/Ly6Chi) and b neutrophils (CD45+/CD11b+/Ly6G+) in NeuT/Ackr2+/+ (white squares),
and NeuT/Ackr2−/− (black squares), Balb/c WT (white triangles), and Ackr2−/− (black triangles) mice (n= 9 for NeuT/Ackr2+/+ and 7 for NeuT/Ackr2−/−,
3 for both WT and Ackr2−/− at 10 and 15 weeks; 6 for NeuT/Ackr2+/+ and 5 for NeuT/Ackr2−/−, 5 for both WT and Ackr2−/− at 25 weeks). c Absolute
number of neutrophils, inﬂammatory monocytes, alveolar (CD11blow/F4/80+/Ly6Cint/CD11c+/Ly6G−) and interstitial macrophages (CD11b+/F4/80int/
Ly6C−/CD11c−/Ly6G−) in the lungs of NeuT/Ackr2+/+ (white columns) and NeuT/Ackr2−/− (black columns) mice at 15 weeks of age (n= 12 for NeuT/
Ackr2+/+ and 6 for NeuT/Ackr2−/− mice). d Representative immunohistochemical images of Ly6G staining in NeuT/Ackr2+/+ and NeuT/Ackr2−/− lungs at
25 weeks of age. Magniﬁcation: ×20. Scale bar: 100 μm. e Quantiﬁcation of Ly6G immunohistochemical images as number of DAB-positive cells on ﬁeld of
view (n= 9 for NeuT/Ackr2+/+ and 8 for NeuT/Ackr2−/− mice, respectively). f Absolute number of neutrophils and inﬂammatory monocytes in the BM of
WT (white columns) and Ackr2−/− (black columns) mice on day 14 after orthotopic injection of 4T1 cells (n= 4 for both WT and Ackr2−/− mice). Data are
represented as mean (SD). p value was generated using the unpaired t-test. *p< 0.05, **p< 0.01, ***p< 0.001
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Ackr2 is expressed by HPCs and controls myelopioesis. Results
with BM chimeras demonstrated that ACKR2 expression by
hematopoietic cells was responsible for the more pronounced
neutrophil mobilization (Fig. 3e, f) and for protection against
metastasis found in Ackr2−/− mice (Supplementary Fig. 1c).
As Ackr2 mRNA expression was very low in neutrophils (Fig. 6b),
we traced its expression on sorted myeloid lineage hematopoietic
precursors (gating strategy Supplementary Fig. 6a). Ackr2
transcript level was highest in Linneg/Sca-1+/cKit+ (LSK) cells,
and was then downregulated in the more mature common
myeloid progenitors (CMPs; Linneg/Sca-1−/cKit+/CD34+/
FcγRII/IIIint) and granulocytes-monocytes progenitors (GMPs;
Linneg/Sca-1−/cKit+/CD34+/FcγRII/IIIhigh) (Fig. 6a, b). Thus, the
most immature progenitors have the highest level of
Ackr2 expression, which then declines during the myeloid
differentiation, showing an opposite behavior as compared to
CCR2, whose expression is upregulated during maturation31
(Fig. 6c).
When we performed expression analysis of other chemokine
receptors, we found that, similarly to neutrophils, LSK, CMPs,
and GMPs isolated from Ackr2−/− mice expressed higher levels of
CCR1, CCR2, and CCR5 compared to WT mice (Fig. 6c,
Supplementary Fig. 6b,c). Fluorescence-activated cell sorting
(FACS) analysis conﬁrmed an increased expression of CCR2 in
Ackr2−/− LSK, CMP, and GMP cells, and revealed that this was
restricted to the myeloid lineage, as no detectable levels of CCR2
were observed in both WT and Ackr2−/− megakaryocyte-
erythroid progenitors (MEPs; Linneg/Sca-1−/cKit+/
CD34−/FcγRII/III−) (Fig. 6d). On the other hand, we did not
ﬁnd differences in CXCR4 mRNA and protein expression in WT
and Ackr2−/− HPCs (Fig. 6e, f, respectively). These results
indicate that ACKR2 is expressed by HPCs and controls the
expression of inﬂammatory CC chemokine receptors known to be
involved in myeloid cell release from BM.
WT and Ackr2−/− BM did not differ in the absolute number of
LSK and CMPs, while a trend of increase was observed in the
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Fig. 3 Hematopoietic expression of ACKR2 increases monocyte and neutrophil mobilization. Absolute number of inﬂammatory monocytes (a) and
neutrophils (b) in the blood of C57BL/6J WT or Ackr2−/− mice 1 h after i.p. injection of CCL3L1 or vehicle (n= 11 for WT/PBS and 8 for Ackr2−/−/PBS, 12
for WT/CCL3L1, and 10 for Ackr2−/−/CCL3L1 for monocytes; n= 8 for both WT/PBS and Ackr2−/−/PBS, 7 for WT/CCL3L1, and 5 for Ackr2−/−/CCL3L1 for
neutrophils). Percentage of monocytes (c) and neutrophils (d) in the BM of the indicated mice 1 h after CCL3L1 or vehicle i.p. injection (n= 19 for WT/PBS
and 15 for Ackr2−/−/PBS, 4 for both WT/CCL3L1, and Ackr2−/−/CCL3L1 for monocytes; n= 12 for both WT/PBS and Ackr2−/−/PBS, 7 for both WT/
CCL3L1, and Ackr2−/−/CCL3L1 for neutrophils). Absolute number of inﬂammatory monocytes (e) and neutrophils (f) in WT and Ackr2−/− mice
reconstituted with either WT (white columns) or Ackr2−/− BM (black columns) after i.p. injection of CCL3L1 (n= 3 for both WT and Ackr2−/− mice). Data
are represented as mean (SD). p value was generated using the unpaired t-test. *p< 0.05, **p< 0.01, ***p< 0.001
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number of GMPs in the BM of Ackr2−/− compared to WT mice
(Supplementary Fig. 6d). In addition, no difference in the
proliferation of hematopoietic progenitors (Supplementary
Fig. 6e) and in the levels of the hematopoietic growth factor
granulocyte colony-stimulating factor (Supplementary Fig. 6f)
was found comparing resting and tumor-bearing WT and
Ackr2−/− mice.
However, LSK cells sorted from BM Ackr2−/− and cultured
in vitro had increased expression of the myeloid differentiation
markers Ly6G, Ly6C, and CD11b, as compared to their WT
counterparts (Fig. 6g–i, respectively). Conversely, induction of
ACKR2 high expression levels by transfection in the human
promyelocytic cell line HL-60, which express low levels of ACKR2
(Supplementary Fig. 6g,h), resulted in a signiﬁcant reduction of
CCR2 and CD11b expression, while no change in CXCR4 levels
was detectable (Fig. 6j). The increased maturation of neutrophils
was also supported by in vivo experiments with a BrdU analog32.
Indeed, in the blood of Ackr2−/− mice there were more mature
neutrophils compared to WT mice (Supplementary Fig. 6i).
Collectively, these data indicate that ACKR2 genetic inactiva-
tion in early hematopoietic precursors results in an accelerated
maturation rate of neutrophils, which are more efﬁciently
mobilized by inﬂammatory chemokines and efﬁciently recruited
to metastatic lesions, where they perform enhanced anti-
metastatic activity. ACKR2 in hematopoietic precursors thus
operates as a checkpoint for myeloid cell mobilization and
effector functions, and its targeting may pave the way to
innovative therapeutic strategies, unleashing myeloid cell-
mediated protection against cancer.
Discussion
Chemokines are essential mediators of cancer-related inﬂamma-
tion. Chemokines and chemokine receptors are downstream of
oncogene activation and inactivation of oncosuppressor genes, as
illustrated by CXCR4 and the VHL pathway1,33. Inﬂammatory
chemokines contribute to shaping the landscape of immunity in
cancer by recruiting tumor-promoting myeloid cells, polarized
Th2 cells, and Treg cells, and by promoting M2-like skewing of
tumor-associated macrophages (TAM)1.
Consistently with this general picture, inactivation of ACKR2,
a decoy and scavenger receptor for inﬂammatory CC chemokines,
was associated with enhanced carcinogenesis in the skin and GI
tract13,14. Conversely, downregulation of ACKR2 driven by Kras
activation is associated with tumor progression in human
Kaposi’s sarcoma and in a mouse vascular tumor model16.
Tuning of monocyte recruitment underlies the regulatory func-
tion of ACKR2 in tumor progression15.
In agreement with this set of previous data we found that in a
model of primary mammary carcinogenesis driven by Her2, an
oncogene involved in human breast cancer, ACKR2 deﬁciency
was associated with accelerated appearance and growth of pri-
mary lesions. Given the tumor-promoting function of TAM in
murine and human breast cancer7,34,35, it is reasonable to assume
that enhanced tumor growth was mediated by macrophages.
Unexpectedly, in the same model, we found that ACKR2 deﬁ-
ciency was associated with protection against metastasis, an
observation in sharp contrast with the primary tumor phenotype.
Protection against lung metastasis in ACKR2-deﬁcient hosts
was also observed in the 4T1 mammary carcinoma line
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transplanted orthotopically and in the classic B16F10 melanoma
cell line injected i.v. The unexpected ﬁnding of protection against
metastasis prompted a dissection of underlying mechanisms
taking advantage of transplanted tumor models.
Several lines of evidence indicate that neutrophils mediate
resistance to metastasis in ACKR2-deﬁcient hosts. ACKR2 deﬁ-
ciency was associated with profound alterations in neutrophil
phenotype and function. Indeed Ackr2−/− neutrophils had
increased ROS production and cell-killing activity, a pattern that
identiﬁes mature or activated neutrophils32. Moreover, neu-
trophils lacking ACKR2 had increased expression of the che-
mokine receptors Ccr1, Ccr2, and Ccr5, a chemokine receptor
proﬁle again typical of activated neutrophils. Indeed, neutrophils
express different pattern of chemokine receptors depending on
their activation state36,37. Interferon-γ, the prototypic Th1 cyto-
kine, upregulates the expression of the CC chemokine receptors
CCR1 and CCR338, and inﬂammatory stimuli such as lipopoly-
saccharide (LPS) induce CCR2 expression in neutrophils39. The
expression of CC chemokine receptors by neutrophils is func-
tionally relevant not only in terms of recruitment to the inﬂamed
site but also in the activation of their effector functions such as
respiratory burst, bacterial killing, and anti-metastatic activ-
ity28,36,40. In line with these data Ackr2-deﬁcient neutrophils
showed increased recruitment to the lungs (Supplementary
Fig. 3d) and increased tumor-killing activity (Fig. 5g) compared
to WT neutrophils.
The role of neutrophils in protection against metastasis was
also demonstrated by depletion experiments. Neutrophil deple-
tion rescued the phenotype of resistance to metastasis observed in
ACKR2-deﬁcient hosts. Interestingly, in ACKR2-competent mice
neutrophil depletion resulted in reduced metastasis (Fig. 4b, c), in
line with several observations of neutrophil-mediated tumor
promotion (see below). Finally, adoptive transfer of ACKR2-
deﬁcient neutrophils mediated resistance against metastasis
(Fig. 4d). Thus, unleashing neutrophil-mediated resistance
underlies protection against metastasis observed in ACKR2-
deﬁcient mice.
The ﬁnding that Ackr2 expression was vanishingly low in
mature neutrophils, raised the possibility of a regulatory function
of this molecule upstream in hematopoiesis. We found that Ackr2
is expressed by HPCs and that it is downregulated during
maturation in myeloid progenitors. Interestingly, ACKR2 was
cloned in 1997 from the BM41 but its role and expression in this
compartment has not been explored42. Here we found that
Ackr2−/− HPCs, like Ackr2−/− neutrophils, express extremely
high levels of the chemokine receptors CCR1, CCR2, and CCR5
and, when cultured with differentiating cytokines, acquire mye-
loid differentiation markers faster compared to WT counterparts.
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To directly assess the effect of ACKR2 on chemokine receptors
in immature hematopoietic elements, the HL-60 cell line was
used. Here ACKR2 downregulated the expression of CCR2 and of
the integrin CD11b. ACKR2 induces a signal transduction cascade
activating a β-arrestin-dependent signaling that optimizes its
chemokine scavenging activity43. It is likely that in HPCs β-
arrestin signaling by ACKR2 negatively controls the expression of
CC chemokine receptors by interfering with other signaling
pathways or by activating mechanism of negative regulation as
previously described for other ACKRs. ACKR3, for example,
negatively controls signaling by CXCR444 and ACKR4 inhibits
the expression of CCR7, CCR9, CXCR5, and CXCR445. Our data
are also consistent with previous published data reporting that
ACKR2 regulates neutrophil migration toward inﬂammatory CC
chemokines46.
Neutrophils have emerged as important players in cancer-
related inﬂammation. In general, several lines of evidence indicate
that neutrophils are part of the inﬂammatory network, which
promotes tumor progression and metastasis47–49. In accordance
with this line of evidence, we observed that neutrophil depletion
using an α-Ly6G monoclonal antibody resulted in decreased lung
metastasis in the B16F10 and in the 4T1 models (Fig. 4b, c).
However, neutrophils can undergo functionally reprogramming
in response to tumor- and host-derived signals48,49 and accord-
ingly exert divergent inﬂuence on tumor growth50, a dichotomy
mirrored by prognostic signiﬁcance in different human cancers51.
Here we report that Ackr2 expressed by HPCs is a key setpoint
of neutrophil differentiation, mobilization, and function (Sup-
plementary Fig. 7). Targeting hematopoietic ACKR2 may pave
the way to innovative therapeutic strategies unleashing myeloid
cell-mediated protection against infection and cancer.
Methods
Cell lines. 4T1 and 4T1-66cl4 cells (kindly provided by Dr. Claudia Chiodoni,
Department of Experimental Oncology and Molecular Medicine, Istituto Nazionale
dei Tumori, Milano, Italy) were grown in Dulbecco’s modiﬁed Eagle medium
(DMEM; Lonza) supplemented with 10% fetal bovine serum (FBS; Sigma), 1%
penicillin/streptomycin (Lonza), 1% L-glutamine (Lonza), 1% sodium pyruvate
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(Lonza), and 1% Hepes (Lonza). B16F10, kindly provided by Prof. Massimiliano
Mazzone (Vesalius Research Center, Leuven, Belgium), were grown in DMEM
(Lonza) supplemented with 10% FBS (Sigma), 1% penicillin/streptomycin (Lonza),
and 1% L-glutamine (Lonza). 4T1-luc from PerkinElmer were grown in RPMI 1640
(Lonza), 10% FBS (Sigma), 1% penicillin/streptomycin (Lonza), 1% L-glutamine
(Lonza), 1% sodium pyruvate (Lonza), and 5.4 g/l glucose (Sigma). HL-60 were
purchased from American Type Culture Collection and grown in Iscove’s modiﬁed
Dulbecco’s medium (IMDM; Lonza), 20% FBS (Sigma), 1% penicillin/streptomycin
(Lonza), 1% L-glutamine (Lonza), and 1% sodium pyruvate (Lonza), and trans-
fected with pEGFP-N1 ACKR2 or mock vector52 by using the Nucleofector Kits for
HL-60 (Lonza) according to the manufacturer’s instructions. Green ﬂuorescent
protein-positive cells were sorted for mRNA analysis. Cells were tested for
mycoplasma and only mycoplasma-free cells were used.
Animals. Ackr2−/− mice were maintained on Balb/c and C57BL/6J genetic back-
ground. Balb/c WT and Ackr2−/− mice were crossed with NeuT mice (kindly
donated by Professor Federica Cavallo, University of Turin, Italy). WT and WT
CD45.1 mice were obtained from Charles River Laboratories (Calco, Italy) or were
co-housed littermates. All colonies were housed and bred in the SPF animal facility
at Humanitas Clinical and Research Center in individually ventilated cages. Mice
used for experiments were 8–12 weeks old. Procedures involving animal handling
and care were conformed to protocols approved by the Humanitas Clinical and
Research Center (Rozzano, Milan, Italy) in compliance with national (4D.L. N.116,
G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council
Directive 2010/63/EU, OJ L 276/33, 22-09-2010; and National Institutes of Health
Guide for the Care and Use of Laboratory Animals, US National Research Council,
2011). The study was approved by the Italian Ministry of Health (approval no. 88/
2013-B, issued on 08 April 2013). All efforts were made to minimize the number of
animals used and their suffering. Mice were randomized based on sex, age, and
weight. The sample size was chosen on the basis of past experience on tumor
models in order to detect differences of at least 20% between the groups. In most
in vivo experiments, the investigators were unaware of the genotype of the
experimental groups.
Tissue collection. Blood was collected from the retro-orbital plexus and by cardiac
puncture as described53. Brieﬂy, blood was collected in 2KD-EDTA spray-coated
tubes (BD Bioscience), washed in FACS buffer (PBS−/−, 1% bovine serum albumin,
and 0.05 % sodium azide), red blood cells were lysed, washed again, and cells were
stained as indicated. Lungs were instilled with PBS for FACS analysis or 4% neutral
buffer formalin for histological analysis. For FACS analysis, lungs were minced,
digested for 45 min in 1 mg/ml collagenase IV (Sigma) in PBS−/−, and ﬁltered with
70 μm cell strainer. Red blood cells were lysed and cells stained as indicated. BM
was collected from femurs and tibiae. Bones were harvested, cleaned, ﬂushed, and
ﬁltered with 70 μm cell strainer. Red blood cells were lysed and cells stained as
indicated below.
Tumor models. Tumor volume was assessed with caliper using the formula:
(length × width × width)/2. Tumor take in NeuT model was determinate by pal-
pation as number of mammary tumors per mouse. For 4T1 and 4T1-66cl4 models
5 × 105 cells were injected in the mammary fat path of Balb/c mice. For lung
metastasis evaluation in NeuT, 4T1, and 4T1-66cl4 models, lungs were instilled and
ﬁxed for 24 h with 4% neutral buffered formalin, routinely processed for parafﬁn
embedding, sectioned at 4 μm thickness, and stained with hematoxylin and eosin.
Sections were evaluated in a blinded fashion under a light microscope. Lung
metastasis in NeuT, 4T1, and 4T1-66cl4 models were classiﬁed according to their
size into: small (<30 neoplastic cells), medium (30–300 neoplastic cells), and large
(>300 neoplastic cells). A total metastatic score was then calculated for each lung as
follows: number of small metastases × 1 + number of medium metastases × 3 +
number of large metastasis × 5. Representative images were acquired with Slide
Scanner VS120 dotSlide (Olympus) and analyzed with ImageJ. The melanoma cell
line B16F10 (2 × 105 cells) was injected i.v. in C57BL/6 mice and metastases were
macroscopically counted as dark nodules on the lung surface. For all the models,
metastatic ratio was calculated as ratio of metastasis in Ackr2−/− or depleted mice
compared to indicated control mice. For monocyte depletion, mice were treated
with 100 μg of α-CD115 antibody (clone AFS98, Bioxcell) the day before 2 × 105
B16F10 injection and every 2 days for the entire duration of the experiment. For
neutrophil depletion, mice were treated with 200 μg of α-Ly6G antibody (clone
1A8, Bioxcell) the day before 2 × 105 B16F10 injection and with 100 μg every 3 days
for the entire duration of the experiment. For B-cell depletion, mice were treated
with 250 μg of α-CD20 (clone 5D2, Genentech Inc.) 3 days before 2 × 105 B16F10
injection. For adoptive transfer experiments, neutrophils were isolated from WT
and Ackr2−/− BM using the Mouse Neutrophil Isolation Kit (Miltenyi Biotec) and
an autoMACS Pro separator (Miltenyi Biotec). Cell purity was assessed by ﬂow
cytometry (CD45, CD11b, and Ly6G) and used only if neutrophils were ≥95% on
CD45+ cells. For B16F10 model, recipient WT mice were injected i.v. with 5 × 106
WT or Ackr2−/− neutrophils every 3 days for the entire duration of the experiment.
For adoptive transfer experiment, recipient CD45.1 mice were injected i.v. with
2 × 106 CD45.2 WT or Ackr2−/− neutrophils 15 min before CCL3L1 (R&D)
injection and after 1 h lung and blood were collected and leukocytes counted by
ﬂow cytometry.
Immunohistochemistry. Serial 4 μm formalin-ﬁxed and parafﬁn-embedded lung
sections were deparafﬁnized and underwent heat-induced epitope retrieval with
pressure cooker. Endogenous peroxidase activity was blocked by incubating sec-
tions in 3% H2O2 for 15 min. Slides were rinsed and treated with Rodent Block M
(Biocare Medical) for 30 min to reduce nonspeciﬁc background staining and then
incubated for 1 h at room temperature with Ly6G antibody (1:200; clone 1A8; BD
Bioscience), Sections were incubated for 30 min with Rat on Mouse HRP-Polymer
kit (Biocare Medical). The immunoreaction was visualized with 3,3′-diamino-
benzidine (Peroxidase DAB Substrate Kit, Vector Laboratories) substrate and
sections were counterstained with Mayer’s hematoxylin. Negative immunohisto-
chemical controls for each sample were prepared by replacing the primary antibody
with normal serum. Positive control sections were included in each immunola-
beling assay. Tissues were dehydrated with ethanol, mounted with Eukitt, and
acquired with an Olympus BX61 virtual slide scanning system using Cell^F soft-
ware (Olympus). In each section 10 independent ﬁeld of view were acquired. To
evaluate the extent of granulocytes inﬁltration in the lung parenchyma, the per-
centage of Ly6G-positive area was analyzed with Image-Pro Analyzer 7.0 (Media
Cybernetics) software. Representative images were generated using the ImageJ
analysis program (http://rsb.info.nih.gov/ij/).
Flow cytometry analysis. Flow cytometry analysis was performed as previously
described53. To exclude dead cells from analysis, cells were stained with Violet dead
cell stain kit (Thermo Fisher). Single-cell suspension was stained with antibodies
listed in Supplementary Table 1 and related isotype. All antibodies were purchased
from BD Bioscience, BioLegend, eBioscience, or AbD Serotec. Flow cytometry data
were acquired using a FACSCanto II (BD Bioscience) and LSR Fortessa (BD
Bioscience), and data were analyzed with FACS Diva (BD Bioscience) and repre-
sentative images were generated with FlowJo Software (Tree Star). To analyze ROS
production, neutrophils were stained with 5 μM CellROX Deep Red Reagent
(Thermo Fisher) for 20 min at 37 °C in RPMI 1% FBS. Staining was blocked on ice,
red blood cells were lysed, and neutrophils were analyzed by ﬂow cytometry within
2 h from the staining. Where indicated, mice were injected with 500 μg of Click-it
EdU Plus (Thermo Fisher) resuspended in PBS. Femurs were harvested 2 h after
injection for hematopoietic progenitor analysis. For neutrophil analysis blood was
collected 48 and 72 h after injection. Staining was performed according to the
manufacturer’s instructions. The absolute number was determined by using Tru-
Count beads (BD Biosciences) according to the manufacturer’s instructions. Cell
sorting was performed using a FACSAria III (BD Bioscience).
HPC isolation and culture. Lineage-negative cells were isolated from WT and
Ackr2−/− BM using LS columns and the Mouse Lineage Cell Depletion Kit (Mil-
tenyi Biotec), according to the manufacturer’s instructions. Negative fraction was
stained with Streptavidin-PB, Sca-1, cKit, CD34, and FcγRII/III antibodies and
sorted. LSK were seed (1 × 103/well) in rounded-bottom 96-well plate in IMDM
medium (Lonza) supplemented with 10% FCS (Sigma), 1% L-glutamine (Lonza),
20 ng/ml stem cell factor (SCF) (Peprotech), 10 ng/ml interleukin (IL)-6 (Pepro-
tech), and 10 ng/ml IL-3 (Peprotech), as previously described54. Cells were har-
vested 3 and 6 days after seeding, stained, and analyzed by ﬂow cytometry.
Leukocyte mobilization. Mice were injected intraperitoneally with 3 μg CCL3L1
(R&D) and after 1 h blood was collected and leukocytes counted by ﬂow cytometry.
To evaluate the percentage of monocytes in BM sinusoids, mice were injected
intravenously with 1 μg Ly6C−PE antibody 2 min before the end of experiment.
Generation of BM chimeras. Recipient mice received gentamycin (0.8 mg/ml) in
drinking water for 2 weeks starting 10 days before irradiation. WT and Ackr2−/−
mice were lethally irradiated with a total dose of 900 cGy. After 2 h, mice were
injected in the retro-orbital plexus with 4 × 106 nucleated BM cells obtained by
ﬂushing of the cavity of a freshly dissected femur from WT or Ackr2−/− donors.
Experiment were performed 16 weeks after irradiation to allow complete myeloid
repopulation.
In vitro cell-killing assay. Neutrophils were isolated by magnetic separation as
described above from blood of 14 days’ 4T1 tumor-bearing mice or from BM of
untreated mice and seeded (1 × 105/well) in a 96-well plate in which, 4 h before,
5 × 103 4T1-luc cells were plated in Optimem (Thermo Fisher) + 0.5% FBS. Cells
were incubated overnight in presence of apocynin 100 μM (Sigma) or dimethyl-
sulfoxide control. Fireﬂy luciferase activity was detected with luciferase assay sys-
tem (Promega) and Synergy H2 (Biotek). Cell killing was calculated as percentage
of tumor lysis by the following formula: % cell killing = (1 −[luminescence of
samples with neutrophils]/[luminescence of samples in medium]) × 100.
Transcript analysis by quantitative PCR. Total RNA was extracted from HPCs
with miRNA easy Mini kit (Qiagen). Reverse transcription was done using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative PCR
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(qPCR) was performed with TaqMan Gene Expression Assays (Thermo Fisher) in
a 7900 HT Fast Real-Time PCR System (Applied Biosystems) with probes listed in
Supplementary Table 2. Total RNA was extracted from HL-60 cells and neutrophils
using the TRIzol reagent (Thermo Fisher). Reverse transcription was done using
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qPCR was
performed with TaqMan Gene Expression Assays in a CFX Connect Real-Time
PCR Detection System (BioRad) with probes listed in Supplementary Table 2.
Relative mRNA expression was determined by using the 2−ΔCt method, and nor-
malized to the expression of the housekeeping gene β-actin or Gapdh.
Statistical analysis. Data are represented as mean. In all ﬁgures sample variation
is shown as SD. p value was generated using the unpaired t-test after normality test
and F test to exclude difference in the variance between groups (GraphPad Prism
5). *p < 0.05, **p< 0.01, ***p< 0.001, ns = not statistically different.
Data availability. The authors declare that all the data supporting the ﬁndings of
this study are available within the article and its supplementary information ﬁles
and from the corresponding author upon reasonable request.
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